1.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NICHD
Protocol IDs: PPRU 10762, NCT00491946
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI
Protocol IDs: COG-ARST0331, NCT00075582, ARST0331
|
|
3.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 3 to 20
Sponsor: NCI
Protocol IDs: HLMCC-0402, NCT00369564, ACCL 0731
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI
Protocol IDs: COG-ARST0531, NCT00354835, ARST0531
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: UCCRC-16227A, 16227A, 8131, NCT00720174
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: 070206, 07-C-0206, NCT00923351
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: MSKCC-03099, NCT00077285
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 70
Sponsor: Other
Protocol IDs: RMBMT-124-A, NCT00304720
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: 04-188, NCT00592592
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: UMN-2007LS072, UMN-2007LS072, UMN-MT2007-07, NCT00617929
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0707, EudraCT Number: 2007-006719-21, NCT00668148
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: umcc 2007.137, HUM00017515, NCT00763490
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 30 years
Sponsor: NCI
Protocol IDs: COG-ADVL0821, ADVL0821, NCT00831844
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-02-C-0031, 02-C-0031, 5425, NCI-5425, NCT00030108
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: PSCI-20615, NCT00112645
|
